Search

Displaying results 4721 - 4730 of 8974 in total
  1. Drug

    Empasiprubart

    go.drugbank.com/drugs/DB16469
    Investigational

    Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. … This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells.

  3. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. … XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  4. Drug

    Sesame oil

    go.drugbank.com/drugs/DB11172
    ApprovedNutraceutical

    Sesame oil is reported to possess antioxidant, antiaging, antihypertensive, immunoregulatory and anticancer properties. It has also shown to accelerate alcohol decomposition in the liver [A27257]. … Sesame oil is considered an indirect additive used in food cotact substances by the FDA.

  5. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    Elafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or … Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system.

  6. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  7. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase. … An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  8. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression. … MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists.

  9. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment … As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  10. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.